Death of a young woman with cyclic vomiting: a case report

Li BUK. Cyclic vomiting syndrome and abdominal migraine. Int Semin Pediatr Gastroenterol. 2000;9:1–9.

Gee S. On fitful or recurrent vomiting. St Bartholomew Hosp Rev. 1882;18:1–6.

Fleisher DR, Matar M. The cyclic vomiting syndrome: a report of 71 cases and literature review. J Pediatr Gastroenterol Nutr. 1993;17:361–9.

Boles RG, Zaki EA, Lavenbarg T, Hejazi R, Foran P, Freeborn J, et al. Are pediatric and adult-onset cyclic vomiting syndrome (CVS) biologically different conditions? Relationship of adult-onset CVS with the migraine and pediatric CVS-associated common mtDNA polymorphisms 16519T and 3010A. Neurogastroenterol Motil. 2009;21:936-e72.

Allen JH, de Moore GM, Heddle R, Twartz JC. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut. 2004;53:1566–70.

Abell TL, Adams KA, Boles RG, Bousvaros A, Chong SK, Fleisher DR, et al. Cyclic vomiting syndrome in adults. Neurogastroenterol Motil. 2008;20:269–84.

Pareek N, Fleisher DR, Abell T. Cyclic vomiting syndrome: what a gastroenterologist needs to know. Am J Gastroenterol. 2007;102:2832–40.

Prakash C, Clouse RE. Cyclic vomiting syndrome in adults: clinical features and response to tricyclic antidepressants. Am J Gastroenterol. 1999;94:2855–60.

Li BU, Balint JP. Cyclic vomiting syndrome: evolution in our understanding of a brain-gut disorder. Adv Pediatr. 2000;47:117–60.

Herlihy JD, Reddy S, Shanker A, McCallum R. Cyclic vomiting syndrome: an overview for clinicians. Expert Rev Gastroenterol Hepatol. 2019;13:1137–43.

Drossman DA, Richter JE, Talley NJ, Thompson WG, Corrazziari E, Whitehead WE. The functional gastrointestinal disorders: diagnosis, pathophysiology and treatment. McLean, VA: Degnon Associates; 1994.

Stanghellini V, Chan FK, Hasler WL, Malagelada JR, Suzuki H, Tack J, et al. Gastroduodenal disorders. Gastroenterology. 2016;150:1380–92.

Suzuki H. The application of the Rome IV criteria to functional esophagogastroduodenal disorders in Asia. J Neurogastroenterol Motil. 2017;23:325–33.

Drossman DA. Functional gastrointestinal disorders: History, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016;150:1262–79.

Nourbakhsh M, Miller A, Gofton J, Jones G, Adeagbo B. Cannabinoid hyperemesis syndrome: Reports of fatal cases. J Forensic Sci. 2019;64:270–4.

Duncan M, Davison JS, Sharkey KA. Review article: endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther. 2005;22:667–83.

Sharkey KA, Darmani NA, Parker LA. Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system. Eur J Pharmacol. 2014;722:134–46.

Van Sickle MD, Oland LD, Ho W, Hillard CJ, Mackie K, Davison JS, et al. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology. 2001;121:767–74.

Richards JR. Cannabinoid hyperemesis syndrome: A disorder of the HPA axis and sympathetic nervous system? Med Hypotheses. 2017;103:90–5.

Lundberg DJ, Daniel AR, Thayer SA. Delta(9)-tetrahydrocannabinol-induced desensitization of cannabinoid-mediated inhibition of synaptic transmission between hippocampal neurons in culture. Neuropharmacology. 2005;49:1170–7.

Darmani NA. Cannabinoid-induced hyperemesis: A conundrum from clinical recognition to basic science mechanisms. Pharmaceuticals (Basel). 2010;3:2163–77.

Cha JM, Kozarek RA, Lin OS. Case of cannabinoid hyperemesis syndrome with long-term follow-up. World J Clin Cases. 2014;2:930–3.

DeVuono MV, Parker LA. Cannabinoid hyperemesis syndrome: A review of potential mechanisms. Cannabis Cannabinoid Res. 2020;5:132–44.

Knowlton MC. Cannabinoid hyperemesis syndrome. Nursing. 2019;49:42–5.

Kim HS, Anderson JD, Saghafi O, Heard KJ, Monte AA. Cyclic vomiting presentations following marijuana liberalization in Colorado. Acad Emerg Med. 2015;22:694–9.

Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA. Cannabinoid hyperemesis syndrome: Diagnosis, pathophysiology, and treatment-a systematic review. J Med Toxicol. 2017;13:71–87.

Hauser L. Canada’s legalization of marijuana offers a blueprint for the U.S. 2019. https://www.statnews.com/2019/03/22/canada-legalize-marijuana-lessons-united-states/. Accessed 5 July 2021.

Matheson J, Le Foll B. Cannabis legalization and acute harm from high potency cannabis products: A narrative review and recommendations for public health. Front Psychiatry. 2020;11:591979.

Soota K, Lee Y-J, Schouweiler K, Keeney M, Nashelsky M, Holm A. Cases of death secondary to cannabinoid hyperemesis syndrome. Am J Gastroenterol. 2016;111(Abstract 2217):S1063.

Trillium Gift of Life Network (TGLN) -- Donation Resource Manual. 2010. https://www.giftoflife.on.ca/resources/pdf/healthcare/6752_TGLN_Donation_Manual_EN_Sept2018.pdf. Accessed 5 July 2021.

Cheungpasitporn W, Suksaranjit P, Chanprasert S. Pathophysiology of vomiting-induced hypokalemia and diagnostic approach. Am J Emerg Med. 2012;30:384.

Rich K. Overview of Mallory-Weiss syndrome. J Vasc Nurs. 2018;36:91–3.

Janjua KJ. Boerhaave’s syndrome. Postgrad Med J. 1997;73:265–70.

Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med. 2001;344:665–71.

White JK, Carver J. Self-induced vomiting as a probable mechanism of an isolated hyoid bone fracture. Am J Forensic Med Pathol. 2012;33:170–2.

Helfant RH. Hypokalemia and arrhythmias. Am J Med. 1986;80:13–22.

Castro D, Sharma S. Hypokalemia. In: StatPearls. Treasure Island (FL). 2020. https://www.ncbi.nlm.nih.gov/pubmed/29494072. Accessed 5 July 2021.

Widimsky P. Hypokalemia and the heart. e-Journal of Cardiology Practice. 2008;7.

Cohagan B, Brandis D. Torsade de pointes. In: StatPearls. Treasure Island (FL). 2020. https://www.ncbi.nlm.nih.gov/pubmed/29083738. Accessed 5 July 2021.

Kovacic K, Sood M, Venkatesan T. Cyclic vomiting syndrome in children and adults: What is new in 2018? Curr Gastroenterol Rep. 2018;20:46.

Vieweg WV. New generation antipsychotic drugs and QTc interval prolongation. Prim Care Companion J Clin Psychiatry. 2003;5:205–15.

Etchegoyen CV, Keller GA, Mrad S, Cheng S, Di Girolamo G. Drug-induced QT interval prolongation in the intensive care unit. Curr Clin Pharmacol. 2017;12:210–22.

Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5:E8-16.

Lapoint J, Meyer S, Yu CK, Koenig KL, Lev R, Thihalolipavan S, et al. Cannabinoid hyperemesis syndrome: Public health implications and a novel model treatment guideline. West J Emerg Med. 2018;19:380–6.

Portman D, Donovan KA. Cannabinoid hyperemesis syndrome: A case report of a confounding entity in oncology care. J Oncol Pract. 2018;14:333–4.

Witsil JC, Mycyk MB. Haloperidol, a novel treatment for cannabinoid hyperemesis syndrome. Am J Ther. 2017;24:e64-7.

Jones JL, Abernathy KE. Successful treatment of suspected cannabinoid hyperemesis syndrome Using haloperidol in the outpatient setting. Case Rep Psychiatry. 2016;2016:3614053.

Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE. Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. SciWorld J. 2012;2012:212178.

Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6:479–87.

Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016;149:139–52.

Soriano-Co M, Batke M, Cappell MS. The cannabis hyperemesis syndrome characterized by persistent nausea and vomiting, abdominal pain, and compulsive bathing associated with chronic marijuana use: a report of eight cases in the United States. Dig Dis Sci. 2010;55:3113–9.

Nicolson SE, Denysenko L, Mulcare JL, Vito JP, Chabon B. Cannabinoid hyperemesis syndrome: a case series and review of previous reports. Psychosomatics. 2012;53:212–9.

Maron MS. Gene test interpretation: Hypertrophic cardiomyopathy genes (MYBPC3, MYH7, TNNT2, TNNI3, MYL2, MYL3, ACTC1, TPM1). 2020. https://www.uptodate.com/. Accessed 5 July 2021.